AstraZeneca Says U.S. Court Decision Favors Symbicort Patents

The U.S. District Court for the Northern District of West Virginia has decided in favor of AstraZeneca in litigation against Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P., determining that asserted claims in three of AstraZeneca’s patents protecting Symbicort (budesonide/formoterol) in the U.S. are not invalid, AstraZeneca says in a statement.

• “AstraZeneca is pleased with the court’s decision, and we maintain full confidence in the strength of our intellectual property rights protecting Symbicort,” says Ruud Dobber, executive vice president of the Biopharmaceuticals Business Unit

To contact the reporter on this story:
Lisa Pham in London at lpham14@bloomberg.net

To ...